South Korea
· Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 4.49 trillion. The enterprise value is 4.27 trillion.
| Market Cap | 4.49T |
| Enterprise Value | 4.27T |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has decreased by -0.09% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | -0.09% |
| Shares Change (QoQ) | +11.45% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 18.93% |
| Float | 9.15M |
Valuation Ratios
The trailing PE ratio is 40.57 and the forward PE ratio is 28.65. PharmaResearch's PEG ratio is 0.76.
| PE Ratio | 40.57 |
| Forward PE | 28.65 |
| PS Ratio | 11.44 |
| PB Ratio | 7.55 |
| P/TBV Ratio | 8.47 |
| P/FCF Ratio | 45.89 |
| P/OCF Ratio | 32.31 |
| PEG Ratio | 0.76 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.97, with an EV/FCF ratio of 43.67.
| EV / Earnings | 38.49 |
| EV / Sales | 10.89 |
| EV / EBITDA | 26.97 |
| EV / EBIT | 29.63 |
| EV / FCF | 43.67 |
Financial Position
The company has a current ratio of 6.45, with a Debt / Equity ratio of 0.35.
| Current Ratio | 6.45 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 1.33 |
| Debt / FCF | 2.15 |
| Interest Coverage | 22.02 |
Financial Efficiency
Return on equity (ROE) is 20.00% and return on invested capital (ROIC) is 13.65%.
| Return on Equity (ROE) | 20.00% |
| Return on Assets (ROA) | 12.27% |
| Return on Invested Capital (ROIC) | 13.65% |
| Return on Capital Employed (ROCE) | 18.02% |
| Revenue Per Employee | 959.19M |
| Profits Per Employee | 271.33M |
| Employee Count | 409 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, PharmaResearch has paid 31.84 billion in taxes.
| Income Tax | 31.84B |
| Effective Tax Rate | 22.99% |
Stock Price Statistics
The stock price has increased by +210.12% in the last 52 weeks. The beta is 0.59, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +210.12% |
| 50-Day Moving Average | 408,100.00 |
| 200-Day Moving Average | 283,509.00 |
| Relative Strength Index (RSI) | 46.94 |
| Average Volume (20 Days) | 156,847 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 392.31 billion and earned 110.97 billion in profits. Earnings per share was 10,648.93.
| Revenue | 392.31B |
| Gross Profit | 284.89B |
| Operating Income | 144.12B |
| Pretax Income | 138.50B |
| Net Income | 110.97B |
| EBITDA | 158.38B |
| EBIT | 144.12B |
| Earnings Per Share (EPS) | 10,648.93 |
Balance Sheet
The company has 458.57 billion in cash and 210.66 billion in debt, giving a net cash position of 247.91 billion or 23,861.63 per share.
| Cash & Cash Equivalents | 458.57B |
| Total Debt | 210.66B |
| Net Cash | 247.91B |
| Net Cash Per Share | 23,861.63 |
| Equity (Book Value) | 594.75B |
| Book Value Per Share | 54,314.47 |
| Working Capital | 489.26B |
Cash Flow
In the last 12 months, operating cash flow was 138.91 billion and capital expenditures -41.11 billion, giving a free cash flow of 97.80 billion.
| Operating Cash Flow | 138.91B |
| Capital Expenditures | -41.11B |
| Free Cash Flow | 97.80B |
| FCF Per Share | 9,413.53 |
Margins
Gross margin is 72.62%, with operating and profit margins of 36.74% and 28.29%.
| Gross Margin | 72.62% |
| Operating Margin | 36.74% |
| Pretax Margin | 35.30% |
| Profit Margin | 28.29% |
| EBITDA Margin | 40.37% |
| EBIT Margin | 36.74% |
| FCF Margin | 24.93% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.26%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.26% |
| Dividend Growth (YoY) | 15.79% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 9.09% |
| Buyback Yield | 0.09% |
| Shareholder Yield | 0.33% |
| Earnings Yield | 2.47% |
| FCF Yield | 2.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 6.45 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.45 |
| Piotroski F-Score | 7 |